AMICUS THERAPEUTICS INC (FOLD)
US03152W1099 - Common Stock
Taking everything into account, FOLD scores 3 out of 10 in our fundamental rating. FOLD was compared to 602 industry peers in the Biotechnology industry. FOLD may be in some trouble as it scores bad on both profitability and health. FOLD is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year FOLD has reported negative net income.
FOLD had a negative operating cash flow in the past year.
FOLD had negative earnings in each of the past 5 years.
In the past 5 years FOLD always reported negative operating cash flow.
1.2 Ratios
FOLD's Return On Assets of -22.72% is fine compared to the rest of the industry. FOLD outperforms 79.93% of its industry peers.
The Return On Equity of FOLD (-130.33%) is worse than 64.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.72% | ||
| ROE | -130.33% | ||
| ROIC | N/A |
ROA(3y)-30.53%
ROA(5y)-35.54%
ROE(3y)-123.51%
ROE(5y)-109.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 90.49%, FOLD belongs to the top of the industry, outperforming 91.64% of the companies in the same industry.
FOLD's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for FOLD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 90.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.11%
GM growth 5Y1.19%
2. Health
2.1 Basic Checks
FOLD does not have a ROIC to compare to the WACC, probably because it is not profitable.
FOLD has more shares outstanding than it did 1 year ago.
FOLD has more shares outstanding than it did 5 years ago.
FOLD has a worse debt/assets ratio than last year.
2.2 Solvency
FOLD has an Altman-Z score of -1.51. This is a bad value and indicates that FOLD is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.51, FOLD is in line with its industry, outperforming 53.01% of the companies in the same industry.
FOLD has a Debt/Equity ratio of 2.96. This is a high value indicating a heavy dependency on external financing.
FOLD's Debt to Equity ratio of 2.96 is on the low side compared to the rest of the industry. FOLD is outperformed by 85.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.96 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.51 |
ROIC/WACCN/A
WACC11.21%
2.3 Liquidity
A Current Ratio of 2.73 indicates that FOLD has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.73, FOLD is doing worse than 72.41% of the companies in the same industry.
FOLD has a Quick Ratio of 2.40. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
FOLD has a worse Quick ratio (2.40) than 74.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.73 | ||
| Quick Ratio | 2.4 |
3. Growth
3.1 Past
FOLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.87%, which is quite impressive.
Looking at the last year, FOLD shows a quite strong growth in Revenue. The Revenue has grown by 15.19% in the last year.
Measured over the past years, FOLD shows a very strong growth in Revenue. The Revenue has been growing by 54.91% on average per year.
EPS 1Y (TTM)35.87%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q41.67%
Revenue 1Y (TTM)15.19%
Revenue growth 3Y21.8%
Revenue growth 5Y54.91%
Revenue growth Q2Q26.68%
3.2 Future
Based on estimates for the next years, FOLD will show a very strong growth in Earnings Per Share. The EPS will grow by 35.65% on average per year.
The Revenue is expected to grow by 28.61% on average over the next years. This is a very strong growth
EPS Next Y44.58%
EPS Next 2Y47.78%
EPS Next 3Y42.16%
EPS Next 5Y35.65%
Revenue Next Year20.76%
Revenue Next 2Y28.23%
Revenue Next 3Y29.46%
Revenue Next 5Y28.61%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for FOLD. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 71.38, FOLD can be considered very expensive at the moment.
FOLD's Price/Forward Earnings ratio is rather cheap when compared to the industry. FOLD is cheaper than 93.81% of the companies in the same industry.
FOLD's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 19.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 71.38 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
FOLD's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
FOLD's earnings are expected to grow with 42.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y47.78%
EPS Next 3Y42.16%
5. Dividend
5.1 Amount
No dividends for FOLD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AMICUS THERAPEUTICS INC
NASDAQ:FOLD (11/29/2023, 3:20:00 PM)
After market: 10.76 0 (0%)10.76
+0.18 (+1.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-08 2023-11-08/bmo
Earnings (Next)02-28 2024-02-28/amc
Inst Owners108.61%
Inst Owner Change0.58%
Ins Owners1.65%
Ins Owner Change1.05%
Market Cap3.09B
Analysts78.89
Price Target17.68 (64.31%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.03%
Min EPS beat(2)-19.24%
Max EPS beat(2)9.17%
EPS beat(4)1
Avg EPS beat(4)-19.45%
Min EPS beat(4)-47.42%
Max EPS beat(4)9.17%
Revenue beat(2)2
Avg Revenue beat(2)1.6%
Min Revenue beat(2)0.11%
Max Revenue beat(2)3.09%
Revenue beat(4)4
Avg Revenue beat(4)1.28%
Min Revenue beat(4)0.1%
Max Revenue beat(4)3.09%
PT rev (1m)-0.64%
PT rev (3m)9.01%
EPS NQ rev (1m)-19.05%
EPS NQ rev (3m)23.07%
EPS NY rev (1m)0%
EPS NY rev (3m)7.56%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)-0.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 71.38 | ||
| P/S | 8.3 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 23.18 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.59
EYN/A
EPS(NY)0.15
Fwd EY1.4%
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS1.3
BVpS0.46
TBVpS-0.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.72% | ||
| ROE | -130.33% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 90.49% | ||
| FCFM | N/A |
ROA(3y)-30.53%
ROA(5y)-35.54%
ROE(3y)-123.51%
ROE(5y)-109.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.11%
GM growth 5Y1.19%
F-Score4
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.96 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 119.86% | ||
| Cap/Sales | 2.25% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.73 | ||
| Quick Ratio | 2.4 | ||
| Altman-Z | -1.51 |
F-Score4
WACC11.21%
ROIC/WACCN/A
Cap/Depr(3y)56.53%
Cap/Depr(5y)147.54%
Cap/Sales(3y)1.22%
Cap/Sales(5y)4.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y (TTM)35.87%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q41.67%
EPS Next Y44.58%
EPS Next 2Y47.78%
EPS Next 3Y42.16%
EPS Next 5Y35.65%
Revenue 1Y (TTM)15.19%
Revenue growth 3Y21.8%
Revenue growth 5Y54.91%
Revenue growth Q2Q26.68%
Revenue Next Year20.76%
Revenue Next 2Y28.23%
Revenue Next 3Y29.46%
Revenue Next 5Y28.61%
EBIT growth 1Y51.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year65.15%
EBIT Next 3Y49.57%
EBIT Next 5Y41.16%
FCF growth 1Y12.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.66%
OCF growth 3YN/A
OCF growth 5YN/A